Do analysts prefer ADTX or VINC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, ADTX or VINC?

Vincerx Pharma has lower revenue, but higher earnings than Aditxt. Vincerx Pharma is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.29 -$41.71M -$100.79 thousand N/A Vincerx Pharma N/A N/A -$40.16M -$5.31 N/A

Is ADTX or VINC more profitable?

Vincerx Pharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Vincerx Pharma's return on equity of -248.33% beat Aditxt's return on equity. Company Net Margins Return on Equity Return on Assets Aditxt -360,152.50% -374.60% -105.93% Vincerx Pharma N/A -248.33% -132.73%

Do analysts rate ADTX or SCPS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scopus BioPharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, ADTX or SCPS?

Scopus BioPharma has lower revenue, but higher earnings than Aditxt. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.29 -$41.71M -$100.79 thousand N/A Scopus BioPharma N/A N/A -$11.61M N/A N/A

Does the media refer more to ADTX or SCPS?

In the previous week, Aditxt had 3 more articles in the media than Scopus BioPharma. MarketBeat recorded 4 mentions for Aditxt and 1 mentions for Scopus BioPharma. Scopus BioPharma's average media sentiment score of 0.99 beat Aditxt's score of 0.38 indicating that Scopus BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aditxt 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Scopus BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ADTX or SMFL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Smart for Life 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, ADTX or SMFL?

Smart for Life has higher revenue and earnings than Aditxt. Smart for Life is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.29 -$41.71M -$100.79 thousand N/A Smart for Life $11.11M 0.00 -$22.68M -$14.48 N/A

Is ADTX or SMFL more profitable?

Smart for Life has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Smart for Life's return on equity of 0.00% beat Aditxt's return on equity. Company Net Margins Return on Equity Return on Assets Aditxt -360,152.50% -374.60% -105.93% Smart for Life N/A N/A N/A

Do analysts prefer ADTX or VRPX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Virpax Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate ADTX or TRVN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Trevena 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, ADTX or TRVN?

Trevena has higher revenue and earnings than Aditxt. Trevena is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.29 -$41.71M -$100.79 thousand N/A Trevena $443K 0.00 -$40.29M -$47.04 N/A

Is ADTX or TRVN more profitable?

Trevena has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Trevena's return on equity of 0.00% beat Aditxt's return on equity. Company Net Margins Return on Equity Return on Assets Aditxt -360,152.50% -374.60% -105.93% Trevena N/A N/A -119.55%

Aditxt (ADTX) Competitors

$0.0051 0.00 (-13.56%)

As of 07/1/2026 03:59 PM Eastern

Compare

ADTX vs. VINC, SCPS, SMFL, VRPX, and TRVN

Should you buy Aditxt stock or one of its competitors? MarketBeat compares Aditxt with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aditxt include Vincerx Pharma (VINC), Scopus BioPharma (SCPS), Smart for Life (SMFL), Virpax Pharmaceuticals (VRPX), and Trevena (TRVN). These companies are all part of the "pharmaceutical products" industry.

How does Aditxt compare to Vincerx Pharma?

Aditxt (NASDAQ:ADTX) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Vincerx Pharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Vincerx Pharma's return on equity of -248.33% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Vincerx Pharma	N/A	-248.33%	-132.73%

Vincerx Pharma has lower revenue, but higher earnings than Aditxt. Vincerx Pharma is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.29	-$41.71M	-$100.79 thousand	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Aditxt has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vincerx Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Aditxt had 4 more articles in the media than Vincerx Pharma. MarketBeat recorded 4 mentions for Aditxt and 0 mentions for Vincerx Pharma. Aditxt's average media sentiment score of 0.38 beat Vincerx Pharma's score of 0.00 indicating that Aditxt is being referred to more favorably in the media.

Company	Overall Sentiment
Aditxt	Neutral
Vincerx Pharma	Neutral

Summary

Vincerx Pharma beats Aditxt on 7 of the 13 factors compared between the two stocks.

How does Aditxt compare to Scopus BioPharma?

Aditxt (NASDAQ:ADTX) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Scopus BioPharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Scopus BioPharma's return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Scopus BioPharma	N/A	N/A	N/A

Aditxt has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.14, indicating that its stock price is 114% less volatile than the broader market.

Scopus BioPharma has lower revenue, but higher earnings than Aditxt.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.29	-$41.71M	-$100.79 thousand	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scopus BioPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Aditxt had 3 more articles in the media than Scopus BioPharma. MarketBeat recorded 4 mentions for Aditxt and 1 mentions for Scopus BioPharma. Scopus BioPharma's average media sentiment score of 0.99 beat Aditxt's score of 0.38 indicating that Scopus BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aditxt	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Scopus BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.5% of Aditxt shares are held by institutional investors. 0.0% of Aditxt shares are held by insiders. Comparatively, 5.1% of Scopus BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Scopus BioPharma beats Aditxt on 6 of the 11 factors compared between the two stocks.

How does Aditxt compare to Smart for Life?

Aditxt (NASDAQ:ADTX) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Smart for Life has higher revenue and earnings than Aditxt. Smart for Life is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.29	-$41.71M	-$100.79 thousand	N/A
Smart for Life	$11.11M	0.00	-$22.68M	-$14.48	N/A

In the previous week, Aditxt had 4 more articles in the media than Smart for Life. MarketBeat recorded 4 mentions for Aditxt and 0 mentions for Smart for Life. Aditxt's average media sentiment score of 0.38 beat Smart for Life's score of 0.00 indicating that Aditxt is being referred to more favorably in the media.

Company	Overall Sentiment
Aditxt	Neutral
Smart for Life	Neutral

Smart for Life has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Smart for Life's return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Smart for Life	N/A	N/A	N/A

Aditxt has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Smart for Life has a beta of 14.79, suggesting that its share price is 1,379% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Smart for Life	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 0.0% of Aditxt shares are owned by insiders. Comparatively, 31.7% of Smart for Life shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Smart for Life beats Aditxt on 9 of the 14 factors compared between the two stocks.

How does Aditxt compare to Virpax Pharmaceuticals?

Aditxt (NASDAQ:ADTX) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Virpax Pharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Aditxt's return on equity of -374.60% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%

Aditxt has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, Virpax Pharmaceuticals has a beta of 2.28, suggesting that its share price is 128% more volatile than the broader market.

Virpax Pharmaceuticals has lower revenue, but higher earnings than Aditxt. Virpax Pharmaceuticals is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.29	-$41.71M	-$100.79 thousand	N/A
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virpax Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

15.5% of Aditxt shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 0.0% of Aditxt shares are held by company insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Aditxt had 4 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 4 mentions for Aditxt and 0 mentions for Virpax Pharmaceuticals. Aditxt's average media sentiment score of 0.38 beat Virpax Pharmaceuticals' score of 0.00 indicating that Aditxt is being referred to more favorably in the media.

Company	Overall Sentiment
Aditxt	Neutral
Virpax Pharmaceuticals	Neutral

Summary

Aditxt beats Virpax Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Aditxt compare to Trevena?

Aditxt (NASDAQ:ADTX) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Trevena has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Trevena's return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Trevena	N/A	N/A	-119.55%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Trevena	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aditxt has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Trevena has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

In the previous week, Aditxt had 4 more articles in the media than Trevena. MarketBeat recorded 4 mentions for Aditxt and 0 mentions for Trevena. Aditxt's average media sentiment score of 0.38 beat Trevena's score of 0.00 indicating that Aditxt is being referred to more favorably in the media.

Company	Overall Sentiment
Aditxt	Neutral
Trevena	Neutral

Trevena has higher revenue and earnings than Aditxt. Trevena is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.29	-$41.71M	-$100.79 thousand	N/A
Trevena	$443K	0.00	-$40.29M	-$47.04	N/A

15.5% of Aditxt shares are held by institutional investors. Comparatively, 13.6% of Trevena shares are held by institutional investors. 0.0% of Aditxt shares are held by insiders. Comparatively, 2.7% of Trevena shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Aditxt beats Trevena on 8 of the 14 factors compared between the two stocks.

Get Aditxt News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADTX vs. The Competition

Export

Metric	Aditxt	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4K	$3.06B	$6.79B	$12.59B
Dividend Yield	N/A	2.01%	2.66%	6.14%
P/E Ratio	0.00	19.53	27.41	25.27
Price / Sales	0.29	342.77	530.69	99.42
Price / Cash	N/A	57.40	47.99	59.26
Price / Book	0.00	4.26	11.04	6.62
Net Income	-$41.71M	$64.45M	$3.57B	$336.83M
7 Day Performance	N/A	4.28%	2.92%	3.25%
1 Month Performance	N/A	4.75%	3.74%	0.92%
1 Year Performance	N/A	29.17%	34.44%	27.62%

Aditxt Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADTX Aditxt	0.9524 of 5 stars	$0.01 -13.6%	N/A	-100.0%	$4K	$14.34K	N/A	60	Gap Up
VINC Vincerx Pharma	N/A	$0.01 flat	N/A	-71.8%	$66K	N/A	N/A	60
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	+66.7%	$17K	N/A	N/A	9
SMFL Smart for Life	N/A	$0.00 flat	N/A	-99.2%	$14K	$11.11M	N/A	110	Gap Down
VRPX Virpax Pharmaceuticals	N/A	$0.01 flat	N/A	N/A	$14K	N/A	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADTX) was last updated on 7/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aditxt (ADTX) Competitors

ADTX vs. VINC, SCPS, SMFL, VRPX, and TRVN

How does Aditxt compare to Vincerx Pharma?

Summary

How does Aditxt compare to Scopus BioPharma?

Summary

How does Aditxt compare to Smart for Life?

Summary

How does Aditxt compare to Virpax Pharmaceuticals?

Summary

How does Aditxt compare to Trevena?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADTX vs. The Competition

Aditxt Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aditxt (ADTX) Competitors

ADTX vs. VINC, SCPS, SMFL, VRPX, and TRVN

How does Aditxt compare to Vincerx Pharma?

Is ADTX or VINC more profitable?

Which has higher valuation and earnings, ADTX or VINC?

Which has more volatility & risk, ADTX or VINC?

Do insiders & institutionals believe in ADTX or VINC?

Do analysts prefer ADTX or VINC?

Does the media prefer ADTX or VINC?

Summary

How does Aditxt compare to Scopus BioPharma?

Is ADTX or SCPS more profitable?

Which has more risk & volatility, ADTX or SCPS?

Which has higher valuation & earnings, ADTX or SCPS?

Do analysts rate ADTX or SCPS?

Does the media refer more to ADTX or SCPS?

Do insiders and institutionals believe in ADTX or SCPS?

Summary

How does Aditxt compare to Smart for Life?

Which has preferable valuation and earnings, ADTX or SMFL?

Does the media refer more to ADTX or SMFL?

Is ADTX or SMFL more profitable?

Which has more volatility & risk, ADTX or SMFL?

Do analysts prefer ADTX or SMFL?

Do insiders & institutionals have more ownership in ADTX or SMFL?

Summary

How does Aditxt compare to Virpax Pharmaceuticals?

Is ADTX or VRPX more profitable?

Which has more risk & volatility, ADTX or VRPX?

Which has better earnings & valuation, ADTX or VRPX?

Do analysts prefer ADTX or VRPX?

Do insiders & institutionals believe in ADTX or VRPX?

Does the media refer more to ADTX or VRPX?

Summary

How does Aditxt compare to Trevena?

Is ADTX or TRVN more profitable?

Do analysts rate ADTX or TRVN?

Which has more risk and volatility, ADTX or TRVN?

Does the media favor ADTX or TRVN?

Which has better valuation and earnings, ADTX or TRVN?

Do institutionals & insiders believe in ADTX or TRVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADTX vs. The Competition

Aditxt Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools